13F Pro

SEC Form 4 reporting owner

Lorrain Daniel S.

Lorrain Daniel S. has filed 22 Form 4 transactions reported between December 23, 2025 and July 9, 2026, as Chief Scientific Officer of Contineum Therapeutics, Inc..

Name as filed: Lorrain Daniel S.

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$517K
12 lines
Companies
1
with Form 4 filings
Latest transaction
Jul 9, 2026
transaction date

Roles and reported holdings

  • CTNMContineum Therapeutics, Inc.
    Dec 23, 2025 – Jul 9, 2026

    Chief Scientific Officer

    Held directly135,202 sh as of Jul 1, 2026 · Form 4

    24 months: $517K sold

Transaction history

All 22 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Jul 9, 2026CTNMChief Scientific OfficerOption exerciseCode M · direct25$25@ $1.01Form 4
Jul 8, 2026CTNMChief Scientific OfficerOption exerciseCode M · direct1,015$1K@ $1.01Form 4
Jul 1, 2026CTNMChief Scientific OfficerOpen-market saleCode S · direct2,501$41K@ $16.24Form 4
Jul 1, 2026CTNMChief Scientific OfficerOpen-market saleCode S · direct5,852$92K@ $15.67Form 4
Jul 1, 2026CTNMChief Scientific OfficerOption exerciseCode M · direct4,183$4K@ $1.01Form 4
Jun 30, 2026CTNMChief Scientific OfficerOption exerciseCode M · direct28,826$29K@ $1.01Form 4
Jun 1, 2026CTNMChief Scientific OfficerOpen-market saleCode S · direct4,170$55K@ $13.16Form 4
May 1, 2026CTNMChief Scientific OfficerOpen-market saleCode S · direct300$4K@ $13.84Form 4
May 1, 2026CTNMChief Scientific OfficerOpen-market saleCode S · direct3,870$51K@ $13.06Form 4
Apr 6, 2026CTNMChief Scientific OfficerOpen-market saleCode S · direct4,170$56K@ $13.43Form 4
Mar 2, 2026CTNMChief Scientific OfficerOpen-market saleCode S · direct4,170$63K@ $15.01Form 4
Feb 25, 2026CTNMChief Scientific OfficerOption exerciseCode M · direct3,824$4K@ $1.01Form 4
Feb 24, 2026CTNMChief Scientific OfficerOption exerciseCode M · direct4,300$4K@ $1.01Form 4
Feb 19, 2026CTNMChief Scientific OfficerOption exerciseCode M · direct100$101@ $1.01Form 4
Feb 11, 2026CTNMChief Scientific OfficerOption exerciseCode M · direct400$404@ $1.01Form 4
Feb 3, 2026CTNMChief Scientific OfficerOpen-market saleCode S · direct1,170$18K@ $15.25Form 4
Feb 3, 2026CTNMChief Scientific OfficerOpen-market saleCode S · direct3,000$44K@ $14.82Form 4
Jan 30, 2026CTNMChief Scientific OfficerGrant or awardCode A · indirect6,500—Form 4
Jan 30, 2026CTNMChief Scientific OfficerGrant or awardCode A · direct160,000—Form 4
Jan 5, 2026CTNMChief Scientific OfficerOpen-market saleCode S · direct500$6K@ $11.13Form 4
Jan 5, 2026CTNMChief Scientific OfficerOpen-market saleCode S · direct3,670$38K@ $10.35Form 4
Dec 23, 2025CTNMChief Scientific OfficerOpen-market saleCode S · direct4,170$51K@ $12.23Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.